COMMUNIQUÉS West-GlobeNewswire

-
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
14/05/2025 -
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
14/05/2025 -
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025 -
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
14/05/2025 -
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025 -
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
14/05/2025 -
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
14/05/2025 -
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
14/05/2025 -
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
14/05/2025 -
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
14/05/2025 -
Altimmune to Participate at Two Upcoming Investor Conferences
14/05/2025 -
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
14/05/2025 -
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
14/05/2025 -
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
14/05/2025 -
Emergent BioSolutions to Participate in Upcoming Investor Conferences
14/05/2025 -
Glass House Brands and LEEF Announce MSA for The Leaf El Paseo Dispensary and Off-Take Agreement
14/05/2025 -
A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients
14/05/2025 -
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
14/05/2025 -
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
14/05/2025
Pages